Press Release

Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit

Two-day event will convene industry leaders to explore strategies to overcome challenges across the product lifecycle — from R&D to global commercialization 

 

Conshohocken, Pa. (May 8, 2024) - Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.  

The two-day virtual event, which kicks off May 14, will feature panel discussions and presentations that cover key topics and considerations across the commercialization journey — from clinical manufacturing and channel strategy to the solutions needed to support efficient global launches, navigate the unique supply chain requirements, and overcome barriers along the patient journey. The event will feature perspective from a wide range of leaders, including experts from companies that have launched or are developing a CGT as well as representatives from patient advocacy groups, trade associations and the U.S. Food and Drug Administration (FDA).  

“We are entering a new era in cell and gene therapy — with new modalities reaching the market and a growing number of products in clinical development, including therapies that target larger patient populations. However, the path to commercialization is complex and lined with potential challenges that can impact product success and patient access,” said Lung-I Cheng, Vice President, and Head of Cell & Gene Therapy Service Line at Cencora. “By bringing together this group, our goal is to foster collaboration and advance best practices that will support the development and commercialization of these groundbreaking therapies and help to ensure they can reach the patients who need them.” 

There are nearly 2,000 CGT clinical trials underway globally, according to the Alliance for Regenerative Medicine (ARM). In the United States and Europe, there could be as many as 17 regulatory decisions on CGTs in 2024.  

During Cencora’s summit, industry experts will examine strategies to overcome barriers at each stage of the product lifecycle — from research and clinical development (R&D) through to global commercialization and patient engagement strategies. The event will be capped by a fireside chat with ARM’s Chief Operating Officer Rita Johnson-Greene, who will reflect on the progress seen in the last five years and offer her perspective on what she expects will happen during the next half-decade.  

A leader in specialty distribution and services, Cencora offers CGT developers support at each stage of the product lifecycle, including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution and patient support services. Through its CGT Integration Hub, Cencora connects provider-facing platforms with patient services support programs to increase visibility across the therapy development and delivery process, streamlining the path-to-care.  

“We believe the next five years hold tremendous promise for this market and patients worldwide, and we continue to invest in solutions to elevate the support we offer to developers to help them bring their products to market,” said Willis Chandler, President of Global Pharma Services at Cencora. “Launching this summit reflects our belief in the promise of cell and gene therapies, as well as our commitment to create a more connected CGT ecosystem and unlock the potential of these therapies.” 

For more information or to register for the event, visit: https://www.cencora.com/campaign/gps/thinklive-2024-cgt-summit.  

About Cencora 
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com 


Media contacts

Need help or have questions?  Send us a message and we'll get back to you soon.